Association of Rising Cost and Use of Oral Anticancer Drugs With Medicare Part D Spending From 2013 Through 2017
- 1 January 2020
- journal article
- letter
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 6 (1) , 154-156
Abstract
This cross-sectional study weighs the proportional associations of rising drug costs and use with increased Medicare Part D spending for a cohort of oral anticancer drugs used from 2013 through 2017.Keywords
This publication has 5 references indexed in Scilit:
- Specialty Drug Pricing and Out-of-Pocket Spending on Orally Administered Anticancer Drugs in Medicare Part D, 2010 to 2019JAMA, 2019
- Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After ApprovalJAMA Internal Medicine, 2017
- Drug Pricing Trends for Orally Administered Anticancer Medications Reimbursed by Commercial Health Plans, 2000-2014JAMA Oncology, 2016
- Steady Increase In Prices For Oral Anticancer Drugs After Market Launch Suggests A Lack Of Competitive PressureHealth Affairs, 2016
- Five Years of Cancer Drug ApprovalsJAMA Oncology, 2015